ALNY Relative Valuation
ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.
Historical Valuation
Alnylam Pharmaceuticals Inc (ALNY) is now in the Fair zone, suggesting that its current forward PS ratio of 11.39 is considered Fairly compared with the five-year average of 17.12. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 270.26 to 478.97 according to relative valuation methord.
Relative Value
Fair Zone
270.26-478.97
Current Price：289.96
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
322.08
P/B
Median3y
-1136.63
Median5y
-669.76
-0.20
FCF Yield
Median3y
-1.06
Median5y
-2.22
Competitors Valuation Multiple
The average P/S ratio for ALNY's competitors is 4.43, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of 11.39, which is 157.35% above the industry average. Given its robust revenue growth of 20.20%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Alnylam Pharmaceuticals Inc (ALNY) currently overvalued or undervalued?
What is Alnylam Pharmaceuticals Inc (ALNY) fair value?
How does ALNY's valuation metrics compare to the industry average?
What is the current P/B ratio for Alnylam Pharmaceuticals Inc (ALNY) as of May 24 2025?
What is the current FCF Yield for Alnylam Pharmaceuticals Inc (ALNY) as of May 24 2025?
What is the current Forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY) as of May 24 2025?